FEMY
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Femasys Inc. (FEMY) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Momentum (D-). The rating has held at C+ for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | B- (3.0) | B (3.2) | B- (3.0) | D- (1.1) | C+ (2.6) | C+ (2.6) |
| 2026-11-04 | B- (3.0) | B (3.2) | B- (3.1) | D- (0.8) | C+ (2.7) | C+ (2.5) |
| 2026-10-28 | B- (3.0) | B (3.2) | B- (3.1) | D- (0.8) | C+ (2.7) | C+ (2.5) |
| 2026-10-21 | B- (3.0) | B (3.2) | B- (3.0) | D- (0.7) | C+ (2.6) | C+ (2.5) |
| 2026-10-14 | B- (3.0) | B (3.2) | B- (3.0) | D- (0.8) | C+ (2.6) | C+ (2.5) |